LISA CHAPMAN: Open Payments
NPI 1265189336 · MANSFIELD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$404 in 22 payments from 7 companies in 2025. Trend: 2023 $150 · 2024 $895 · 2025 $404
Food & beverage: $404
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $159 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| ABBVIE INC. | 2 | $46 |
| Sage Therapeutics, LLC | 1 | $33 |
| Neurocrine BioSciences, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: ARISTADA, REXULTI, VRAYLAR, ZURZUVAE, INGREZZA, Qelbree, CAPLYTA.
Industry payments across MA — which companies pay providers there.
